好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Cross-Sectional Study of Home Blood Pressure Monitoring after Stroke
Cerebrovascular Disease and Interventional Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
6-015

In individuals with hypertension, lowering blood pressure after stroke can lower the risk of stroke recurrence, but many patients do not reach goal.  Home blood pressure monitoring (HBPM) can help patients achieve their goal. However, rates of use and quality of technique have not been evaluated, which we aim to evaluate in this cross-sectional study.

Hypertension (HTN) affects approximately 70% of patients with a recent stroke and treatment is highly effective in reducing risk for recurrence. In multiple studies the reduction of blood pressure, by life style changes or pharmacotherapy have significantly reduced the risk for fatal or non-fatal stroke. Therefore, blood pressure lowering is effective for secondary stroke prevention.

We conducted a cross-sectional study of patients with stroke.  Patients were eligible if they had a stroke within two years, had hypertension, and lived at home.  We classified patients as correctly performing HBPM if they used an arm cuff, sat >1 min before measurement, took >2 measurements, and use within 6 months.  The primary outcome was determine HBPM was used correctly. Which we calculated according to race and ethnicity.  We ask for additional steps if BP out of range.

Among 150 participants, 120 (81%) possessed a HBPM and 29 (21%) used it correctly.  We observed no significant disparity in rates of possession or correct use between non-Hispanic White participants and participants from underrepresented groups.  Seventy percent of non-Hispanic White patients said they would contact their provider if their BP was above goal vs. 52% of underrepresented patients (p=0.21). 

Most patients after stroke have a HBPM, but only about 1 in 5 use it correctly.  Approximately half of patients from underrepresented racial or ethnic groups do not have a plan for responding to values above goal.  Our results indicate opportunities to improve the dissemination and correct use of HBPM.

Authors/Disclosures
Melissa Mariscal, MD
PRESENTER
Dr. Mariscal has nothing to disclose.
Rachel Forman, MD (Yale Neurology) Dr. Forman has nothing to disclose.
No disclosure on file
No disclosure on file
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Lauren H. Sansing, MD Dr. Sansing has nothing to disclose.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Richa Sharma, MD (Massachusetts General Hospital, Brigham, Harvard) Dr. Sharma has received research support from NIH. Dr. Sharma has received intellectual property interests from a discovery or technology relating to health care.
Walter N. Kernan, MD (Yale Medical School) Dr. Kernan has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for various law firms.